Show simple item record

dc.contributor.authorLaue, Christiane
dc.contributor.authorStevens, Yala
dc.contributor.authorvan Erp, Monique
dc.contributor.authorPapazova, Ekaterina
dc.contributor.authorSoeth, Edlyn
dc.contributor.authorPannenbeckers, Angelika
dc.contributor.authorStolte, Ellen
dc.contributor.authorBöhm, Ruwen
dc.contributor.authorGall, Sophie Le
dc.contributor.authorFalourd, Xavier
dc.contributor.authorBallance, Simon
dc.contributor.authorKnutsen, Svein H
dc.contributor.authorPinheiro, Iris
dc.contributor.authorPossemiers, Sam
dc.contributor.authorRyan, Paul M
dc.contributor.authorRoss, R Paul
dc.contributor.authorStanton, Catherine
dc.contributor.authorWells, Jerry M
dc.contributor.authorWerf, Sylvie van der
dc.contributor.authorMes, Jurriaan J
dc.contributor.authorSchrezenmeir, Juergen
dc.date.accessioned2021-10-25T23:30:27Z
dc.date.available2021-10-25T23:30:27Z
dc.date.issued2021-08-02
dc.identifier.issn2072-6643
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/329863
dc.description.abstractSenior individuals can suffer from immunosenescence and novel strategies to bolster the immune response could contribute to healthy ageing. In this double-blind, randomised, controlled pilot trial, we investigated the ability of non-digestible polysaccharide (NPS) preparations to enhance the immune response in a human vaccination model. In total, 239 subjects (aged 50-79 years) were randomised to consume one of five different NPS (yeast β-glucan (YBG), shiitake β-glucan (SBG), oat β-glucan (OBG), arabinoxylan (AX), bacterial exopolysaccharide (EPS)) or control (CTRL) product daily for five weeks. After two weeks of intervention, subjects were vaccinated with seasonal influenza vaccine. The post-vaccination increases in haemagglutination inhibition antibody titres and seroprotection rate against the influenza strains were non-significantly enhanced in the NPS intervention groups compared to CTRL. Specifically, a trend towards a higher mean log2 fold increase was observed in the AX group (uncorrected p = 0.074) combined with a trend for an increased seroprotection rate, AX group (48.7%) compared to CTRL (25.6%) (uncorrected p = 0.057), for the influenza A H1N1 strain. Subjects consuming AX also had a reduced incidence of common colds compared to CTRL (1 vs. 8; p = 0.029 in Fisher exact test). No adverse effects of NPS consumption were reported. The findings of this pilot study warrant further research to study AX as an oral adjuvant to support vaccine efficacy.
dc.format.mediumElectronic
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectInfluenza A virus
dc.subjectPolysaccharides
dc.subjectInfluenza Vaccines
dc.subjectAdjuvants, Immunologic
dc.subjectHemagglutination Inhibition Tests
dc.subjectImmunization, Secondary
dc.subjectAdministration, Oral
dc.subjectPilot Projects
dc.subjectDouble-Blind Method
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectInfluenza, Human
dc.subjectInfluenza A Virus, H1N1 Subtype
dc.subjectHealthy Volunteers
dc.titleAdjuvant Effect of Orally Applied Preparations Containing Non-Digestible Polysaccharides on Influenza Vaccination in Healthy Seniors: A Double-Blind, Randomised, Controlled Pilot Trial.
dc.typeArticle
prism.issueIdentifier8
prism.publicationDate2021
prism.publicationNameNutrients
prism.volume13
dc.identifier.doi10.17863/CAM.77308
dcterms.dateAccepted2021-07-29
rioxxterms.versionofrecord10.3390/nu13082683
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-08-02
dc.contributor.orcidBöhm, Ruwen [0000-0003-1007-3011]
dc.contributor.orcidFalourd, Xavier [0000-0002-6716-2982]
dc.contributor.orcidRyan, Paul M [0000-0001-7251-6725]
dc.contributor.orcidRoss, R Paul [0000-0003-4876-8839]
dc.identifier.eissn2072-6643
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-08-02


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International